LWCFA
EDIT icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Editas Medicine EDIT Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29
Closed -$1K – 732
2021
Q3 		$1K Hold
29
– – ﹤0.01% 731
2021
Q2 		$2K Buy
+29
New +$1.07K ﹤0.01% 848

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's EDIT Position: Q4 2021 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 29 shares — an estimated $1K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in EDIT in Q2 2021 and held it in 2 quarters. The position peaked at $2K in Q2 2021. 306 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 29 Editas Medicine shares in Q4 2021, an estimated $1K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Editas Medicine in Q2 2021 and held it in 2 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Editas Medicine position peaked at $2K in Q2 2021.
  • 306 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.